Molecular Genetics of Arrhythmias and Cardiovascular Conditions Associated with Arrhythmias

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 11, 2003, Pages 1259-1272

  Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; ALCOHOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOSINE DERIVATIVE; DIMENHYDRINATE; DISOPYRAMIDE; DNA; FLECAINIDE; MESSENGER RNA; PILSICAINIDE; POTASSIUM CHANNEL; PROCAINAMIDE; PROPAFENONE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; THYMINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOL INTOXICATION; AMINO ACID SEQUENCE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BARTTER SYNDROME; BRUGADA SYNDROME; CALCIUM HOMEOSTASIS; CARDIOVASCULAR SYSTEM; CHROMOSOME; CHROMOSOME 10Q; CHROMOSOME DELETION; CLINICAL FEATURE; CODON; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA SEQUENCE; DNA SYNTHESIS; ELECTROCARDIOGRAM; EMERY DREIFUSS MUSCULAR DYSTROPHY; ENVIRONMENTAL FACTOR; FEVER; FIBROSING ALVEOLITIS; GENE MUTATION; GENETIC HETEROGENEITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DILATATION; HEART DISEASE; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEMODYNAMICS; HEREDITY; HUMAN; HUMAN GENOME; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; METABOLIC DISORDER; MOLECULAR GENETICS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; QT INTERVAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX CHROMOSOME; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION; SUDDEN DEATH; T WAVE; X CHROMOSOME; Y CHROMOSOME;

ARRHYTHMIA; BUNDLE-BRANCH BLOCK; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; PHENOTYPE;

EID: 0344394945     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.03316.x     Document Type: Review

References (134)

1. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al: The sequence of the human genome. Science 2001;291:1304-1351.
2. Brugada P, Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992;20:1391-1396.
3. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P: Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101:510-515.
4. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000;11:1320-1329.
5. Priori SG, Napolitano C, Gasparini M, Pappone C, Della BP, Brignole M, Giordano U, Giovannini T, Menozzi C, Bloise R, Crotti L, Terreni L, Schwartz PJ: Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation 2000;102:2509-2515.
6. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA: Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002;106:2514-2519.
7. Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, Nademanee K, Brugada R, Brugada J, Veerakul G, Li H, Bowles NE, Brugada P, Antzelevitch C, Towbin JA: Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002;11:337-345.
8. Brugada P, Brugada J, Brugada R: Arrhythmia induction by antiarrhythmic drugs. Pacing Clin Electrophysiol 2000;23:291-292.
9. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27:1061-1070.
10. Babaliaros VC, Hurst JW: Tricyclic antidepressants and the Brugada syndrome: An example of Brugada waves appearing after the administration of desipramine. Clin Cardiol 2002;25:395-398.
11. Goldgran-Toledano D, Sideris G, Kevorkian JP: Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002;346:1591-1592.
12. Tada H, Sticherling C, Oral H, Morady F: Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol 2001;12:275.
13. Pastor A, Nunez A, Cantale C, Cosio FG: Asymptomatic Brugada syndrome case unmasked during dimenhydrinate infusion. J Cardiovasc Electrophysiol 2001;I2:1192-1194.
14. Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C: Aborted sudden death, transient Brugada pattern, and wide QRS dysrhythmias after massive cocaine ingestion. J Electrocardiol 2001;34:345-349.
15. Nogami A, Nakao M, Kubota S, Sugiyasu A, Doi H, Yokoyama K, Yumoto K, Tamaki T, Kato K, Hosokavva N, Sagai H, Nakamura H, Nitta J, Yamauchi Y, Aonuma K: Enhancement of J-ST-segment elevation by the glucose and insulin test in Brugada syndrome. Pacing Clin Electrophysiol 2003;26:332-337.
16. Antzelevitch C: The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268-272.
17. Yan GX, Antzelevitch C: Cellular basis for the electrocardiographic J wave. Circulation 1996;93:372-379.
18. Antzelevitch C: The Brugada syndrome: Ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268-272.
19. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR: The Brugada syndrome: Clinical, electrophysiological and genetic aspects. J Am Coll Cardiol 1999;33:5-15.
20. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999;100:1660-1666.
21. Lukas A, Antzelevitch C: Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. The antiarrhythmic effects of 4-aminopyridine. Cardiovasc Res 1996;32:593-603.
22. Antzelevitch C, Brugada P, Brugada J, Brugada R, Shimizu W, Gussak I, Perez Riera AR: Brugada syndrome: A decade of progress. Circ Res 2002;91:1114-1118.
23. Kurita T, Shimizu W, Inagaki M, Suyama K, Taguchi A, Satomi K, Aihara N, Kamakura S, Kobayashi J, Kosakai Y: The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome. J Am Coll Cardiol 2002;40:330-334.
24. Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ, Scornik FS, Antzelevitch C: Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002;106:2004-2011.
25. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schultze-Bahr E, Keating MT, Towbin JA, Wang Q: Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998;392:293-296.
26. Priori SG, Napolitano C, Gasparini M, Pappone C, Della BP, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J: Natural history of Brugada syndrome: Insights for risk stratification and management. Circulation 2002;105:1342-1347.
27. Tan HL, Bezzina CR, Smits JP, Verkerk AO, Wilde AA: Genetic control of sodium channel function. Cardiovasc Res 2003;57:961-973.
28. Balser JR: The cardiac sodium channel: Gating function and molecular pharmacology. J Mol Cell Cardiol 2001;33:599-613.
29. Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko VV, Nesterenko DV, Brugada R, Antzelevitch C: Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999;85:803-809.
30. Antzelevitch C, Brugada R: Fever and the Brugada syndrome. Pacing Clin Electrophysiol 2002;25:1637-1639.
31. Weiss R, Barmada MM, Nguyen T, Seibel JS, Cavlovich D, Kornblit CA, Angelilli A, Villanueva F, McNamara DM, London B: Clinical and molecular heterogeneity in the Brugada syndrome. A novel gene locus on chromosome 3. Circulation 2002;105:707-713.
32. Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, Haverkamp W, Breithardt G, Escande D, Schulze-Bahr E, LeMarec H, Wilde AA: Genotype-phenotype relationship in Brugada syndrome: Electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 2002;40:350-356.
33. Schwartz PJ: The idiopathic long QT syndrome: Progress and questions. Am Heart J 1985;109:399-411.
34. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer JW, Hall WJ, Weitkamp LR, Vincent GM, Garson A, Robinson JL, Benhorin J, Choi S: The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991;84:1136-1144.
35. Zipes DP: The long QT interval syndrome: A Rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation 1991;84:1414-1419.
36. Wang Q, Shen J, Splawski I, Atkinson DL, Li ZZ, Robinson JL, Moss AJ, Towbin JA, Keating MT: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805-811.
37. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V: Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003;421:634-639.
38. Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, Clark J, Deymeer F, George AL Jr, Fish FA, Hahn A, Nitu A, Ozdemir C, Serdaroglu P, Subramony SH, Wolfe G, Fu YH, Ptacek LJ: Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001;105:511-519.
39. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
40. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, Van Raay TJ, Shen J, Timothy KW, Vincent GM, De Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12:17-23.
41. Ks function. Nat Genet 1997;17:338-340.
42. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN: The QT interval. Prog Cardiovasc Dis 2001;43:1-45.
43. Tomaselli GF, Marban E: Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:270-283.
44. Sipido KR, Volders PG, De Groot SH, Verdonck F, Van de WF, Wellens HJ, Vos MA: Enhanced Ca(2+) release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 2000;102:2137-2144.
45. Volders PG, Sipido KR, Vos MA, Spatjens RL, Leunissen JD, Carmeliet E, Wellens HJ: Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 1999;100:2455-2461.
46. Undrovinas AI, Maltsev VA, Sabbah HN: Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 1999;55:494-505.
47. Maltsev VA, Sabbah HN, Higgins RS, Silverman N, Lesch M, Undrovinas AI: Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998;98:2545-2552.
48. Antzelevitch C, Dumaine R: Electrical heterogeneity in the heart: Physiological, pharmacological and clinical implications. In: Page E, Fozzard HA, Solaro RJ, eds: Handbook of Physiology. The Heart. New York: Oxford University Press, 2002:654-692.
49. Antzelevitch C, Shimizu W: Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002;17:43-51.
50. Shimizu W, Antzelevitch C: Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000;102:706-712.
51. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R: Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation (Online) 2001;103:89-95.
52. Shimizu W, Antzelevitch C: Cellular basis for the electrocardiographic features of the LQT1 form of the long QT syndrome: Effects of β-adrenergic agonists, antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998;98:2314-2322.
53. Ali RH, Zareba W, Moss A, Schwartz PJ, Benhorin J, Vincent GM, Locati EH, Priori S, Napolitano C, Towbin JA, Hall WJ, Robinson JL, Andrews ML, Zhang L, Timothy K, Medina A: Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol 2000;85:457-461.
54. Shimizu W, Antzelevitch C: Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997;96:2038-2047.
55. Shimizu W, Antzelevitch C: Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000;35:778-786.
56. Noda T, Takaki H, Kurita T, Suyama K, Nagaya N, Taguchi A, Aihara N, Kamakura S, Sunagawa K, Nakamura S, Ohe T, Horie M, Napolitano C, Towbin JA, Priori S, Shimizu W: Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and forms of congenital long QT syndrome. Eur Heart J 2002;23:975-983.
57. Antzelevitch C: Sympathetic modulation of the long QT syndrome. Eur Heart J 2002;23:1246.
58. Keating MT, Atkinson DL, Dunn C, Timothy KW, Vincent GM, Leppert M: Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 1991;252:704-706.
59. Keating MT, Atkinson DL, Dunn C, et al: Consistent linkage of the long QT syndrome to the Harvey ras-1 locus on chromosome 11. Am J Hum Genet 1991;49:1335-1339.
60. Benhorin J, Kalman YM, Medina A, Towbin JA, Raveharel N, Dyer TD, Blangero J, MacCluer JW, Kerem BS: Evidence of genetic heterogeneity in the long QT syndrome. Science 1993;260:1960-1962.
61. Curran ME, Atkinson DL, Timothy KW, Vincent GM, Moss AJ, Leppert M, Keating MT: Locus heterogeneity of autosomal dominant long QT syndrome. J Clin Invest 1993;92:799-803.
62. 2+ and modulated by cAMP. Nature 1993;365:445-448.
63. Warmke J, Drysdale R, Ganetzky B: A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science 1991;252:1560-1562.
64. Warmke JW, Ganetzky B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-3442.
65. Jiang C, Atkinson DL, Towbin JA, Splawski I, Lehmann MH, Li HGG, Timothy KW, Taggart RT, Schwartz PJ, Vincent GM, Moss AJ, Keating MT: Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nat Genet 1994;8:141-147.
66. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-95.
67. Kr potassium channel. Cell 1995;81:299-307.
68. Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour JB, Donnelly P, Vergnaud G, Bachner L, Moisan JP, Le Marec H, Pascal O: Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995;57:1114-1122.
69. Takumi T, Ohkubo H, Nakanishi S: Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science 1988;242:1042-1045.
70. Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH: Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome. Circulation 1998;97:142-146.
71. Zhang M, Jiang M, Tseng GN: minK-related peptide 1 associates with Kv4.2 and modulates its gating function: Potential role as beta subunit of cardiac transient outward channel? Circ Res 2001;88:1012-1019.
72. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, Coumel P, Petit C, Schwartz K, Guicheney P: A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 1997;15:186-189.
73. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW: ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995;92:2929-2934.
74. Ali RH, Zareba W, Moss AJ, Schwartz PJ, Benhorin J, Vincent GM, Locati EH, Priori S, Napolitano C, Towbin JA, Hall WJ, Robinson JL, Andrews ML, Zhang L, Timothy K, Medina A: Clinical and genetic variables associated with acute arousal and nonarousal-related cardiac events among subjects with long QT syndrome. Am J Cardiol 2000;85:457-461.
75. Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, Shen J, Splawski I, Priori SG, Compton SJ, Yanowitz F, Benhorin J, Moss AJ, Schwartz PJ, Robinson JL, Wang Q, Zareba W, Keating MT, Towbin JA, Napolitano C, Medina A: Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000;102:2849-2855.
76. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ: Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998;339:960-965.
77. Windle JR, Geletka RC, Moss AJ, Zareba W, Atkins DL: Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol 2001;6:153-158.
78. Roden DM: Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001;50:224-231.
79. Shimizu W, Antzelevitch C: Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 as well as LQT3 models of the long QT syndrome. (Abstract) Pacing Clin Electrophysiol 1997;20:1234.
80. Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, Cappuccio FP, Sagnella GA, Kass RS, Keating MT: Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297:1333-1336.
81. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM: Congenital and acquired long QT syndrome. Eur Heart J 2000;21:1232-1237.
82. Kyndt F, Probst V, Potet F, Demolombe S, Chevallier JC, Baro I, Moisan JP, Boisseau P, Schott JJ, Escande D, Le Marec H: Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001;104:3081-3086.
83. Probst V, Kyndt F, Potet F, Trochu JN, Mialet G, Demolombe S, Schott JJ, Baro I, Escande D, Le Marec H: Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease. J Am Coll Cardiol 2003;41:643-652.
84. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K: Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001;103:485-490.
85. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A: Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002;106:69-74.
86. Marks AR, Priori S, Memmi M, Kontula K, Laitinen PJ: Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. J Cell Physiol 2002;190:1-6.
87. Lahat H, Pras E, Olender T, Avidan N, Ben Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M: A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001;69:1378-1384.
88. Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L, Brugada J, Girona J, Domingo A, Bachinski LL, Roberts R: Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997;336:905-911.
89. Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, Jin HW, Sun H, Su XY, Zhuang QN, Yang YQ, Li YB, Liu Y, Xu HJ, Li XF, Ma N, Mou CP, Chen Z, Barhanin J, Huang W: KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299:251-254.
90. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R, Hassan AS: Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-1831.
91. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H: Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:1215-1220.
92. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R: Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001;104:3030-3033.
93. Raben N, Plotz P, Byrne BJ: Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002;2:145-166.
94. Nikoskelainen EK, Savontaus ML, Huoponen K, Antila K, Hartiala J: Pre-excitation syndrome in Leber's hereditary optic neuropathy. Lancet 1994;344:857-858.
95. Corrado D, Fontaine G, Marcus FI, McKenna WJ, Nava A, Thiene G, Wichter T: Arrhythmogenic right ventricular dysplasia/cardiomyopathy: Need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation 2000;101:E101-E106.
96. Corrado D, Basso C, Buja G, Nava A, Rossi L, Thiene G: Right bundle branch block, right precordial ST-segment elevation, and sudden death in young people. Circulation 2001;103:710-717.
97. Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, Nava A, Silvestri F, Blomstrom-Lundqvist C, Wlodarska EK, Fontaine G, Camerini F: Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: A multicenter study. J Am Coll Cardiol 1997;30:1512-1520.
98. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, Norman M, Baboonian C, Jeffery S, McKenna WJ: Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000;355:2119-2124.
99. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo A: Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001;10:189-194.
100. Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, Zimbello R, Simionati B, Basso C, Thiene G, Towbin JA, Danieli GA: Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002;71:1200-1206.
101. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA: Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200.
102. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR: PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000;101:365-376.
103. Towbin JA, Bowles NE: The failing heart. Nature 2002;415:227-233.
104. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO: Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996;276:199-204.
105. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J: Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-538.
106. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F: Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-864.
107. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ: Hypertrophic cardiomyopathy: Histopathological features of sudden death in cardiac troponin T disease. Circulation 2001;104:1380-1384.
108. Maron BJ, Anan TJ, Roberts WC: Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation 1981;63:882-894.
109. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-789.
110. Berger RD, Kasper EK, Baughman KL, Marban E, Calkins H, Tomaselli GF: Beat-to-beat QT interval variability: Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997;96:1557-1565.
111. Marian AJ, Roberts R: The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-670.
112. Jansen GA, Ofman R, Ferdinandusse S, Ijlst L, Muijsers AO, Skjeldal OH, Stokke O, Jakobs C, Besley GT, Wraith JE, Wanders RJ: Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet 1997;17:190-193.
113. Ashizawa T, Subramony SH: What is Kearns-Sayre syndrome after all? Arch Neurol 2001;58:1053-1054.
114. Korade-Mirnics Z, Babitzke P, Hoffman E: Myotonic dystrophy: Molecular windows on a complex etiology. Nucleic Acids Res 1998;26:1363-1368.
115. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-468.
116. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG: A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62:999-1006.
117. Mestroni L, Rocco C, Gregori D, Sinagra G, Di Lenarda A, Miocic S, Vatta M, Pinamonti B, Muntoni F, Caforio AL, McKenna WJ, Falaschi A, Giacca M, Camerini: Familial dilated cardiomyopathy: Evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999;34:181-190.
118. Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baughman KL: The causes of dilated cardiomyopathy: A clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994;23:586-590.
119. D'Adamo P, Fassone L, Gedeon A, Janssen EA, Bione S, Bolhuis PA, Barth PG, Wilson M, Haan E, Orstavik KH, Patton MA, Green AJ, Zammarchi E, Donati MA, Toniolo D: The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997;61:862-867.
120. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE: Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343:1688-1696.
121. Brugada R, Roberts R: The molecular genetics of arrhythmias and sudden death. Clin Cardiol 1998;21:553-560.
122. Fatkin D, MacRae C, Sasaki T, MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ Jr, Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Muehle G, Johnson W, McDonough B: Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999;341:1715-1724.
123. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG: Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000;342:770-780.
124. Muntoni F, Wilson L, Marrosu G, Marrosu MG, Cianchetti C, Mestroni L, Ganau A, Dubowitz V, Sewry C: A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest 1995;96:693-699.
125. Armoundas AA, Tomaselli GF: Electrical and structural remodeling of the ventricular myocardium in disease. In:Gussak HM, Antzelevitch C, eds: Cardiac Repolarization. Bridging Basic and Clinical Science. Totowa, NJ: Humana Press, 2003:127-152.
126. Bryant SM, Shipsey SJ, Hart G: Regional differences in electrical and mechanical properties of myocytes from guinea-pig hearts with mild left ventricular hypertrophy. Cardiovasc Res 1997;35:315-323.
127. Keung ECH, Aronson RS: Transmembrane action potentials and the electrocardiogram in rats with renal hypertension. Cardiovasc Res 1981;15:611-614.
128. 2+ in left ventricular myocyte sub-types from rabbits with heart failure. Cardiovasc Res 2000;45:397-409.
129. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD: QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329.
130. Kaab S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, Kass DA, Marban E, Tomaselli GF: Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996;78:262-273.
131. Vos MA, van Opstal JM, Leunissen JD, Verduyn SC: Electrophysiologic parameters and predisposing factors in the generation of drug-induced torsade de pointes arrhythmias. Pharmacol Ther 2001;92:109-122.
132. Marban E: Heart failure: The electrophysiologic connection. J Cardiovasc Electrophysiol 1999;10:1425-1428.
133. Tomaselli GF, Marban E: Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:270-283.
134. Ramakers C, Vos MA, Doevendans PA, Schoenmakers M, Wu YS, Scicchitano S, Iodice A, Thomas GP, Antzelevitch C, Dumaine R: Coordinated down-regulation of KCNQ1 and KCNE1 expression contributes to reduction of I(Ks) in canine hypertrophied hearts. Cardiovasc Res 2003;57:486-496.